Literature DB >> 34357415

On Left Ventricle Stroke Work Efficiency in Children with Moderate Aortic Valve Regurgitation or Moderate Aortic Valve Stenosis.

M Asaadi1,2, W Mawad3, A Djebbari4, Z Keshavardz-Motamed5, N Dahdah3, L Kadem6.   

Abstract

The optimal timing for management of pediatric patients with moderate aortic valve disease [moderate aortic stenosis (modAS) or moderate aortic regurgitation (modAR)] remains unknown and largely unexplored. Although usually asymptomatic, the risk of increased left ventricular (LV) wall stress, irreversible myocardial fibrosis and sudden death in untreated moderate conditions warrants clearer risk stratification for appropriate timely intervention. In this study, we explore the use of a patient-specific mathematical model to introduce a new evaluative parameter of LV performance in patients with moderate aortic valve disease. Synthetic patient data (N = 520) representing healthy patients, and patients with modAS or modAR were first generated. Then, data from twenty-five pediatric patients were included in this study (healthy = 9; moderate AS = 8; modAR = 8). The effect of modAS or modAR on LV performance was evaluated by LV stroke work (LVSW) efficiency, a new non-invasive parameter. The results demonstrate that healthy patients possess a very high LVSW efficiency (synthetic data: 91 ± 2%, in vivo data: 92 ± 3%). However, modAS patients have a significant reduction in LVSW efficiency (synthetic data: 78 ± 2%, in vivo data: 76 ± 5%, p < 0.05), whereas modAR patients had the lowest LVSW efficiency (synthetic data: 58 ± 3%, in vivo data: 66 ± 7%; p < 0.05). This highlights that patients with moderate aortic valve disease require careful myocardial assessment, regardless of onset of clinical symptoms as their LV performance is significantly reduced. The evaluation of LVSW efficiency offers a promising avenue for future stratification of mixed aortic valve disease for optimal timing of management and intervention.
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Left ventricle energy performance; Mathematical modeling; Moderate aortic regurgitation; Moderate aortic stenosis; Moderate aortic valve disease

Mesh:

Year:  2021        PMID: 34357415     DOI: 10.1007/s00246-021-02690-2

Source DB:  PubMed          Journal:  Pediatr Cardiol        ISSN: 0172-0643            Impact factor:   1.655


  15 in total

Review 1.  Normal values for Doppler echocardiographic assessment of heart valve prostheses.

Authors:  Raphael Rosenhek; Thomas Binder; Gerald Maurer; Helmut Baumgartner
Journal:  J Am Soc Echocardiogr       Date:  2003-11       Impact factor: 5.251

2.  Aortic stenosis: even mild disease is significant.

Authors:  Catherine M Otto
Journal:  Eur Heart J       Date:  2004-02       Impact factor: 29.983

3.  Modeling the impact of concomitant aortic stenosis and coarctation of the aorta on left ventricular workload.

Authors:  Z Keshavarz-Motamed; J Garcia; P Pibarot; E Larose; L Kadem
Journal:  J Biomech       Date:  2011-09-28       Impact factor: 2.712

4.  2017 AHA/ACC Focused Update of the 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.

Authors:  Rick A Nishimura; Catherine M Otto; Robert O Bonow; Blase A Carabello; John P Erwin; Lee A Fleisher; Hani Jneid; Michael J Mack; Christopher J McLeod; Patrick T O'Gara; Vera H Rigolin; Thoralf M Sundt; Annemarie Thompson
Journal:  J Am Coll Cardiol       Date:  2017-03-15       Impact factor: 24.094

Review 5.  Viewpoint: the ENIGMAS trial - when should we treat patients with moderate aortic stenosis?

Authors:  Alexandru Nicolae Mischie; Catalina Liliana Andrei; Crina Sinescu
Journal:  Echocardiography       Date:  2012-12-12       Impact factor: 1.724

6.  Timing of Dynamic NT-proBNP and hs-cTnT Response to Exercise Challenge in Asymptomatic Children with Moderate Aortic Valve Regurgitation or Moderate Aortic Valve Stenosis.

Authors:  Wadi Mawad; Sylvia Abadir; Anne Fournier; Jean-Luc Bigras; Daniel Curnier; Lyes Kadem; Nagib Dahdah
Journal:  Pediatr Cardiol       Date:  2015-06-30       Impact factor: 1.655

7.  Mild and moderate aortic stenosis. Natural history and risk stratification by echocardiography.

Authors:  Raphael Rosenhek; Ursula Klaar; Michael Schemper; Christine Scholten; Maria Heger; Harald Gabriel; Thomas Binder; Gerald Maurer; Helmut Baumgartner
Journal:  Eur Heart J       Date:  2004-02       Impact factor: 29.983

8.  2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.

Authors:  Catherine M Otto; Rick A Nishimura; Robert O Bonow; Blase A Carabello; John P Erwin; Federico Gentile; Hani Jneid; Eric V Krieger; Michael Mack; Christopher McLeod; Patrick T O'Gara; Vera H Rigolin; Thoralf M Sundt; Annemarie Thompson; Christopher Toly
Journal:  J Am Coll Cardiol       Date:  2020-12-17       Impact factor: 24.094

9.  Hemodynamic changes following aortic valve bypass: a mathematical approach.

Authors:  Emilia Benevento; Abdelghani Djebbari; Zahra Keshavarz-Motamed; Renzo Cecere; Lyes Kadem
Journal:  PLoS One       Date:  2015-04-16       Impact factor: 3.240

10.  Non-invasive determination of left ventricular workload in patients with aortic stenosis using magnetic resonance imaging and Doppler echocardiography.

Authors:  Zahra Keshavarz-Motamed; Julio Garcia; Emmanuel Gaillard; Romain Capoulade; Florent Le Ven; Guy Cloutier; Lyes Kadem; Philippe Pibarot
Journal:  PLoS One       Date:  2014-01-28       Impact factor: 3.240

View more
  1 in total

1.  Reducing Morbidity and Mortality in Patients With Coarctation Requires Systematic Differentiation of Impacts of Mixed Valvular Disease on Coarctation Hemodynamics.

Authors:  Reza Sadeghi; Benjamin Tomka; Seyedvahid Khodaei; Julio Garcia; Javier Ganame; Zahra Keshavarz-Motamed
Journal:  J Am Heart Assoc       Date:  2022-01-13       Impact factor: 6.106

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.